The FDA grants fast track designation to PHST001, an antibody targeting CD24, for advanced platinum-resistant and ...

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ...

Bank of America Corp DE reduced its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) by 72.1% ...

The study enrolled adults with platinum-resistant, FRα-expressing high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal ... when cancer cells stop responding to chemotherapy ...

Case study highlights how clinical operations teams can overcome complex regulatory and operational hurdles to finish a trial ...

Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...

The FDA recently granted fast track designation to PHST001, an investigational anti-CD24 monoclonal antibody, for the ...

A new study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer—and offers a potential pathway ...

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.

A new kind of cancer treatment is emerging—one that turns the patient’s own body into a drug factory. Here's what you need to ...

In the final part of an interview with Brian Slomovitz, MD, he highlights that the phase 3 ROSELLA trial demonstrates a safe, effective treatment for platinum-resistant ovarian cancer that does not ...